Investment analysts at Mizuho assumed coverage on shares of FibroGen, Inc (NASDAQ:FGEN) in a report released on Wednesday. The brokerage set a “neutral” rating and a $61.00 price target on the biopharmaceutical company’s stock. Mizuho’s target price would suggest a potential upside of 7.58% from the company’s previous close.

Other research analysts have also issued research reports about the company. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research report on Tuesday, September 12th. Citigroup Inc. reiterated a “buy” rating and set a $48.00 price target on shares of FibroGen in a research report on Monday, June 26th. BidaskClub lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a research report on Friday, July 21st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $65.67.

Shares of FibroGen (FGEN) opened at 56.70 on Wednesday. The firm has a 50-day moving average price of $49.37 and a 200-day moving average price of $34.92. FibroGen has a 12-month low of $15.60 and a 12-month high of $60.15. The firm’s market cap is $4.04 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. On average, equities research analysts expect that FibroGen will post ($1.80) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “FibroGen, Inc (FGEN) Now Covered by Mizuho” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/fibrogen-inc-fgen-now-covered-by-mizuho/1611650.html.

In other news, VP Pat Cotroneo sold 2,851 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the sale, the vice president now owns 157,405 shares in the company, valued at $7,783,677.25. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the company’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $33.45, for a total value of $66,900.00. Following the completion of the sale, the director now owns 32,000 shares of the company’s stock, valued at approximately $1,070,400. The disclosure for this sale can be found here. In the last 90 days, insiders sold 542,828 shares of company stock valued at $25,858,047. Insiders own 14.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. acquired a new stake in shares of FibroGen in the first quarter valued at $111,000. Quantbot Technologies LP acquired a new stake in shares of FibroGen in the second quarter valued at $128,000. SG Americas Securities LLC lifted its holdings in shares of FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the period. Amalgamated Bank acquired a new stake in shares of FibroGen in the second quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of FibroGen by 589.1% in the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 6,327 shares during the period. Institutional investors and hedge funds own 47.49% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.